Skip to main content
bioAffinity Technologies, Inc. logo

bioAffinity Technologies, Inc. — Investor Relations & Filings

Ticker · BIAF ISIN · CA09064N1033 US Professional, scientific and technical activities
Open in API
Filings indexed 334 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country US United States of America
Listing US BIAF

About bioAffinity Technologies, Inc.

https://bioaffinitytech.com/

bioAffinity Technologies, Inc. is a company focused on developing noninvasive diagnostics and targeted therapeutics for cancer. Its first commercialized product, CyPath® Lung, is a non-invasive laboratory developed test for the early detection of lung cancer. The test is designed for individuals at high risk who have suspicious but indeterminate findings on a low-dose computed tomography (LDCT) scan. CyPath® Lung analyzes patient sputum samples using an automated flow cytometry platform and machine learning to identify cell populations indicative of cancer. This approach aims to improve diagnostic accuracy, reduce unnecessary invasive procedures, and lower associated healthcare costs. The company's core technology is based on a proprietary porphyrin platform that preferentially targets cancer cells, with ongoing research to expand its application to other diagnostics and therapeutics.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 8% confidence The document is a Form 8‐K current report filed under the Securities Exchange Act, containing an “Other Events” item disclosing a press release and attached exhibit. It does not present financial statements or constitute an earnings release, shareholder vote result, management discussion, or other specific category. It is a general regulatory announcement (SEC filing). According to the instructions, the appropriate classification for miscellaneous regulatory filings like a Form 8‐K is RNS.
2026-06-02 English
8-K
Regulatory Filings Classification · 90% confidence The document is a Form 8-K Current Report filed under the Securities Exchange Act, providing an Other Events disclosure and referencing a press release as an exhibit. It does not contain financial statements or substantive financial data, nor does it pertain to board changes, dividends, earnings results, or other specialized categories. Therefore, it is classified as a general regulatory filing.
2026-05-27 English
S-8
Regulatory Filings Classification · 75% confidence The document is a Form S-8 Registration Statement under the Securities Act of 1933, used to register securities (shares) under the company’s 2024 Equity Incentive Compensation Plan. It is not an annual or interim financial report, earnings release, management discussion, or capital markets presentation. It is a standard SEC registration filing for employee benefit plan shares, which does not fit other specific categories. Therefore, it falls into the general “Regulatory Filings” category.
2026-05-20 English
424B3
Regulatory Filings Classification · 80% confidence The document is a Form 424B3 prospectus filed under Rule 424(b)(3) with the SEC, relating to the resale of common stock by selling stockholders. It is a regulatory offering document (prospectus) rather than a financial report, earnings release, proxy statement, or management discussion. It does not present audited financial results, management analysis, or voting materials. There is no evidence of an AGM presentation, M&A communication, or dividend notice. As such, it is best categorized under the general “Regulatory Filings” fallback (RNS).
2026-05-14 English
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
Regulatory Filings Classification · 92% confidence The document is a United States SEC Form 8-K “Current Report” filed under the Securities Exchange Act of 1934. It contains Item 8.01 (Other Events) announcing a press release and exhibits, and includes the required signature block. It is not a full annual or quarterly report, earnings release, or certification of financial statements, but rather a miscellaneous regulatory filing under the Exchange Act. Therefore it falls under the “Regulatory Filings” category (RNS).
2026-05-12 English
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
Earnings Release Classification · 90% confidence The document is a Form 8-K current report filed under Item 2.02 “Results of Operation and Financial Condition.” It specifically attaches a press release disclosing first quarter financial results for the period ended March 31, 2026. This is an initial announcement of quarterly financial results (key highlights) rather than a full interim report or merely a notice of publication. It therefore corresponds to an Earnings Release. Q1 2026
2026-05-08 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.